CJC-1295 / Ipamorelin Blend

Overview

This blend combines two growth-hormone secretagogues in one vial: CJC-1295 without DAC (also called Modified GRF 1-29) and Ipamorelin. A common market presentation is 5 mg of each for 10 mg total, and this entry assumes that 5 mg + 5 mg ratio unless a supplier states otherwise. It is reconstituted with bacteriostatic water and injected subcutaneously, with both peptides delivered together in every dose.

Evidence Quality

Both components have human pharmacology data showing they raise growth hormone and IGF-1, which is stronger mechanistic support than most repair blends carry. What is thin is controlled outcome data for muscle, fat and aging at these microgram doses, and no trial has tested this specific fixed combination. The grade reflects a well-established hormonal mechanism paired with limited long-term clinical evidence.

What the Research Shows

CJC-1295 without DAC is a short-acting GHRH analog that increases the size of natural GH pulses (see the CJC-1295 page), while Ipamorelin is a selective ghrelin-receptor agonist that triggers a clean GH release without strongly affecting cortisol or prolactin (see the Ipamorelin page). Used together the two act on different receptors and are commonly described as complementary, raising GH more than either alone in short studies. Downstream effects on body composition are inferred from GH and IGF-1 biology rather than proven at these doses.

Dosage Notes

Doses are usually measured in micrograms of each peptide taken together, delivered from the fixed 1:1 blend. Reconstituting the 10 mg vial with 2 mL of bacteriostatic water gives 5 mg/mL; a 4-unit (0.04 mL) draw then delivers 0.2 mg of total blend, or 100 mcg CJC-1295 plus 100 mcg Ipamorelin. Typical routines use 100 to 200 mcg of each, once or twice daily, injected on an empty stomach and often before bed, in cycles of about 8 to 12 weeks.

Who Should Be Cautious

Anyone with active or prior cancer is generally advised to avoid GH secretagogues, since GH and IGF-1 can promote cell growth. People with diabetes or poor glucose control should be careful because raising GH can reduce insulin sensitivity, and those with a history of carpal tunnel or fluid retention may notice symptoms. It has not been established as safe in pregnancy or breastfeeding.

Availability

The blend is sold for research use only. Neither peptide is FDA-approved for these purposes, and products are typically labeled not for human consumption, with identity and dosing accuracy varying by supplier.

Bottom Line

Of the blends here this one rests on the firmest mechanism, because both peptides demonstrably raise growth hormone in humans, but the real-world benefits at microgram doses are still poorly quantified. Treat expected body-composition gains as plausible rather than proven, and see the CJC-1295 and Ipamorelin pages for detail on each component.